Blog
About

8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Skeletal muscle hypertrophy and atrophy signaling pathways.

      The International Journal of Biochemistry & Cell Biology

      metabolism, p38 Mitogen-Activated Protein Kinases, Up-Regulation, Ubiquitin-Protein Ligases, Transcription Factors, TOR Serine-Threonine Kinases, Signal Transduction, SKP Cullin F-Box Protein Ligases, Protein Kinases, Phosphatidylinositol 3-Kinases, NF-kappa B, Muscular Atrophy, pathology, Muscle, Skeletal, Muscle Proteins, Models, Biological, Insulin-Like Growth Factor I, Hypertrophy, Humans, Glycogen Synthase Kinase 3, Gene Expression Regulation

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Skeletal muscle hypertrophy is defined as an increase in muscle mass, which in the adult animal comes as a result of an increase in the size, as opposed to the number, of pre-existing skeletal muscle fibers. The protein growth factor insulin-like growth factor 1 (IGF-1) has been demonstrated to be sufficient to induce skeletal muscle hypertrophy. Over the past few years, signaling pathways which are activated by IGF-1, and which are responsible for regulating protein synthesis pathways, have been defined. More recently, it has been show that IGF-1 can also block the transcriptional upregulation of key mediators of skeletal muscle atrophy, the ubiquitin-ligases MuRF1 and MAFbx (also called Atrogin-1). Further, it has been demonstrated recently that activation of the NF-kappaB transcription pathway, activated by cachectic factors such as TNFalpha, is sufficient to induce skeletal muscle atrophy, and this atrophy occurs in part via NF-kappaB-mediated upregulation of MuRF1. Further work has demonstrated a trigger for MAFbx expression upon treatment with TNFalpha--the p38 MAPK pathway. This review will focus on the recent progress in the understanding of molecular signalling, which governs skeletal muscle atrophy and hypertrophy, and the known instances of cross-regulation between the two systems.

          Related collections

          Author and article information

          Journal
          10.1016/j.biocel.2005.04.018
          16087388

          Comments

          Comment on this article